Work

A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors

Year: 2015

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-015-0298-3

Authors: Autumn J. McRee, Hanna K. Sanoff, Cheryl Carlson, Anastasia Ivanova, Bert H. O’Neil

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G2912107510, UNC Oncology K12, G4720334866, Use and Comparative Effectiveness of Innovative Therapies for Hepatocellular Carc

OpenAlex ID: W2175789037

FWCI: 2.027

Cites: 17

Cited by: 54

Related to: 10